152 related articles for article (PubMed ID: 33427389)
1. Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study.
Verwijst J; Westerberg E; Punga AR
Eur J Neurol; 2021 May; 28(5):1706-1715. PubMed ID: 33427389
[TBL] [Abstract][Full Text] [Related]
2. Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.
Chuang WY; Ströbel P; Bohlender-Willke AL; Rieckmann P; Nix W; Schalke B; Gold R; Opitz A; Klinker E; Inoue M; Müller-Hermelink HK; Saruhan-Direskeneli G; Bugert P; Willcox N; Marx A
J Autoimmun; 2014 Aug; 52():122-9. PubMed ID: 24373506
[TBL] [Abstract][Full Text] [Related]
3. Extrathymic malignancies in thymoma patients with and without myasthenia gravis.
Owe JF; Cvancarova M; Romi F; Gilhus NE
J Neurol Sci; 2010 Mar; 290(1-2):66-9. PubMed ID: 20034637
[TBL] [Abstract][Full Text] [Related]
4. Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.
Rigamonti A; Lauria G; Piamarta F; Fiumani A; Agostoni E
J Neurol Sci; 2011 Mar; 302(1-2):112-3. PubMed ID: 21236448
[TBL] [Abstract][Full Text] [Related]
5. Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes.
Yamada Y; Weis CA; Thelen J; Sticht C; Schalke B; Ströbel P; Marx A
Front Immunol; 2020; 11():664. PubMed ID: 32373124
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.
Klein R; Marx A; Ströbel P; Schalke B; Nix W; Willcox N
Hum Immunol; 2013 Sep; 74(9):1184-93. PubMed ID: 23792059
[TBL] [Abstract][Full Text] [Related]
7. Extrathymic malignancies in patients with myasthenia gravis.
Levin N; Abramsky O; Lossos A; Karussis D; Siegal T; Argov Z; Ben Hur T
J Neurol Sci; 2005 Oct; 237(1-2):39-43. PubMed ID: 15990114
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for tumor occurrence in patients with myasthenia gravis.
Citterio A; Beghi E; Millul A; Evoli A; Mantegazza R; Antozzi C; Baggi F; Cornelio F; Durelli L; Clerico M; Piccolo G; Cosi V
J Neurol; 2009 Aug; 256(8):1221-7. PubMed ID: 19330280
[TBL] [Abstract][Full Text] [Related]
9. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
[TBL] [Abstract][Full Text] [Related]
10. [Development of myasthenia gravis after thymectomy for thymoma].
Spalek P
Rozhl Chir; 1995 Mar; 74(2):100-2. PubMed ID: 7761941
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of anti-interferon -α2 and anti-interferon -ω antibody in myasthenia gravis].
Qi Y; Zhang LJ; Zhang QX; Wang J; Yang L
Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(41):3227-3231. PubMed ID: 31694117
[No Abstract] [Full Text] [Related]
12. Thymoma related myasthenia gravis in humans and potential animal models.
Marx A; Porubsky S; Belharazem D; Saruhan-Direskeneli G; Schalke B; Ströbel P; Weis CA
Exp Neurol; 2015 Aug; 270():55-65. PubMed ID: 25700911
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
Monte G; Spagni G; Damato V; Iorio R; Marino M; Evoli A
J Neurol; 2021 May; 268(5):1803-1807. PubMed ID: 33387011
[TBL] [Abstract][Full Text] [Related]
14. Anti-skeletal muscle and anti-acetylcholine receptor antibodies in patients with thymoma without myasthenia gravis: relation to the onset of myasthenia gravis.
Ohta M; Itoh M; Hara H; Itoh N; Nishitani H; Hayashi K; Ohta K
Clin Chim Acta; 1991 Sep; 201(3):201-5. PubMed ID: 1756593
[TBL] [Abstract][Full Text] [Related]
15. The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation.
Menghesha H; Schroeter M; Nelke C; Ruck T; Schlachtenberger G; Welskop C; Camo A; Heldwein M; Bennink G; Wahlers T; Bölükbas S; Doerr F; Hekmat K
Neurol Res Pract; 2023 Jun; 5(1):24. PubMed ID: 37316910
[TBL] [Abstract][Full Text] [Related]
16. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?
Choi Decroos E; Hobson-Webb LD; Juel VC; Massey JM; Sanders DB
Muscle Nerve; 2014 Jan; 49(1):30-4. PubMed ID: 23625360
[TBL] [Abstract][Full Text] [Related]
17. Seronegative myasthenia gravis associated with malignant thymoma.
Richards J; Howard JF
Neuromuscul Disord; 2017 May; 27(5):417-418. PubMed ID: 28238572
[TBL] [Abstract][Full Text] [Related]
18. Thymoma pathology and myasthenia gravis outcomes.
Menon D; Katzberg H; Barnett C; Pal P; Bezjak A; Keshavjee S; Bril V
Muscle Nerve; 2021 Jun; 63(6):868-873. PubMed ID: 33675078
[TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis and autoimmune Addison disease in a patient with thymoma.
Seker M; Gozu HI; Oven Ustaalioğlu BB; Sonmez B; Erkal FY; Kocak M; Barisik NO; Orbay E; Sargin M; Sargin H; Boru UT; Yaylaci M
Clin Lung Cancer; 2009 Sep; 10(5):367-70. PubMed ID: 19808197
[TBL] [Abstract][Full Text] [Related]
20. Antititin antibody in early- and late-onset myasthenia gravis.
Szczudlik P; Szyluk B; Lipowska M; Ryniewicz B; Kubiszewska J; Dutkiewicz M; Gilhus NE; Kostera-Pruszczyk A
Acta Neurol Scand; 2014 Oct; 130(4):229-33. PubMed ID: 24947881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
